Protein Kinase C Signaling Mechanisms in Cancer
Protein Kinase C Signaling Mechanisms in Cancer
批准号:
9248796
负责人:
Alan P. Fields
金额:
$39.13万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1999
资助国家:
美国
项目状态:
已结题
起止时间:
1999-04-02 至 2018-06-30
关键词:
AcyltransferaseAllelesAlpha CellAnimal ModelBehaviorBindingBinding ProteinsCancer EtiologyCell NucleolusCell ProliferationCellsCessation of lifeChIP-seqClinicComplexCyclic AMP-Dependent Protein KinasesCytoplasmDataDevelopmentEnzymesErinaceidaeFundingGenesGeneticGenetic TranscriptionGoalsGrowthGuanine Nucleotide Exchange FactorsHumanImmuneIn VitroKnock-outLigandsLocationLungLung NeoplasmsMaintenanceMalignant NeoplasmsMalignant neoplasm of lungMediatingMessenger RNAModelingMolecularMusNon-Small-Cell Lung CarcinomaOncogenesOncogenicPARD6A genePhenotypePhosphorylationPlayProductionPrognostic MarkerPromoter RegionsProtein KinaseProtein Kinase CRNA chemical synthesisRecruitment ActivityRegulationRibosomal RNARoleSignal PathwaySignal TransductionStem cellsTP53 geneTertiary Protein StructureTestingTranscriptional ActivationTranscriptional RegulationTransferaseTranslatingTumor InitiatorsTumorigenicityUnited Statesbasecancer cellcell transformationclinically relevantin vivoin vivo Modelinsightlung tumorigenesisnovelpluripotencypre-clinicalprognosticpromoterpublic health relevancesmoothened signaling pathwaystemstromelysin 2targeted treatmenttherapeutic targettreatment strategytumortumor progression
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Our long-term goals are to elucidate protein kinase C (PKC) signaling mechanisms that contribute to cancer and translate these mechanistic insights into better prognostic and treatment strategies. In previous funding periods, we discovered that PKCι is an oncogene in non-small cell lung cancer (NSCLC) the leading cause of cancer death in the United States, elucidated a major oncogenic PKCι signaling pathway, and developed a therapeutic agent that targets oncogenic PKCι signaling that is currently being evaluated in the clinic. During the current funding period we showed that: 1) PKCι forms an oncogenic PKCι/Par6 signaling complex in the cytoplasm of NSCLC cells that is necessary for cell proliferation and invasion in vitro, and tumor formation in vivo; 2) the guanine nucleotide exchange factor (GEF) Ect2 binds the PKCι/Par6 complex and activates Rac1, a key downstream effector of this complex; 3) PKCι regulates the intracellular location and oncogenic activity of Ect2 through direct binding and phosphorylation; 4) matrix metalloproteinase 10 (Mmp10) is a critical downstream effector of the PKCι/Ect2/Par6/Rac1 signaling axis that is required for NSCLC cell proliferation and invasion in vitro, and Kras-mediated lung tumorigenesis in vivo; and 5) both PKCι and Mmp10 are required for Kras-mediated transformation of bronchio-alveolar stem cells (BASCs), putative lung tumorinitiating cells (TICs) in vivo. Our preliminary studies indicate that: 1) the PKCι/Ect2/Par6/Rac1/Mmp10 signaling axis maintains a tumor-initiating cell phenotype in NSCLC cells characterized by stem-like behavior and enhanced tumorigenicity; 2) a significant pool of cellular Ect2 localizes to the nucleolus in a PKCι- dependent manner where it regulates ribosomal RNA (rRNA) transcription; 3) PKCι transcriptionally activates cell autonomous hedgehog (Hh) signaling in NSCLC tumor-initiating cells; and 4) PKCι regulates recruitment of the stem cell pluripotency factor Sox2 to th promoter region of the gene encoding Hedgehog Acyl Transferase (HHAT), an enzyme that catalyzes a key step in the production of Hh ligand. Based on these data, we hypothesize that: 1) PKCι-mediated transformation involves regulation of Ect2 nucleolar localization and pre-ribosomal RNA synthesis; 2) Ect2 signaling is required for Kras-mediated BASC transformation and lung tumorigenesis in vivo; 3) PKCι maintains a lung tumor-initiating cell phenotype, at least in part, through Sox2-mediated induction of HHAT transcription and activation of a cell autonomous Hh signaling axis; and 4) HHAT, a PKCι-dependent transcriptional target, plays a key role in lung tumor-initiating activity in vivo. These hypotheses will be tested through completion of four interrelated specific aims to: 1) determine the mechanism by which PKCι and Ect2 regulate ribosomal RNA transcription; 2) assess the role of Ect2 in Kras-mediated lung tumorigenesis; 3) determine the mechanism by which PKCι regulates hedgehog acyl-transferase (HHAT) expression; and 4) assess the role of HHAT in lung tumorigenesis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Investigating cells of origin and oncogenic modifiers of 3q26-driven LUSC
-
批准号:10593501
-
项目类别:
-
资助金额:$7.37万
-
财政年份:2021
-
负责人:Alan P. Fields
-
依托单位:
A Genetically Tractable Mouse Model for PRKCI-driven Lung Squamous Cell Carcinoma
-
批准号:10653913
-
项目类别:
-
资助金额:$35.08万
-
财政年份:2021
-
负责人:Alan P. Fields
-
依托单位:
A Genetically Tractable Mouse Model for PRKCI-driven Lung Squamous Cell Carcinoma
-
批准号:10296271
-
项目类别:
-
资助金额:$35.8万
-
财政年份:2021
-
负责人:Alan P. Fields
-
依托单位:
A Genetically Tractable Mouse Model for PRKCI-driven Lung Squamous Cell Carcinoma
-
批准号:10413236
-
项目类别:
-
资助金额:$35.08万
-
财政年份:2021
-
负责人:Alan P. Fields
-
依托单位:
Therapeutic targeting of Kras-driven Lung Adenocarcinoma
-
批准号:9303312
-
项目类别:
-
资助金额:$35.8万
-
财政年份:2016
-
负责人:Alan P. Fields
-
依托单位:
The pathophysiology and palliation of the paclitaxel-induced acute pain syndrome
-
批准号:8930932
-
项目类别:
-
资助金额:$17.21万
-
财政年份:2014
-
负责人:Alan P. Fields
-
依托单位:
Combined PKCiota and mTOR inhibition for treatment of advanced squamous lung canc
-
批准号:8299006
-
项目类别:
-
资助金额:$32.77万
-
财政年份:2011
-
负责人:Alan P. Fields
-
依托单位:
Combined PKCiota and mTOR inhibition for treatment of advanced squamous lung canc
-
批准号:8110919
-
项目类别:
-
资助金额:$34.2万
-
财政年份:2011
-
负责人:Alan P. Fields
-
依托单位:
Atypical PKC signaling in lung cancer stem cells
-
批准号:8244684
-
项目类别:
-
资助金额:$8.42万
-
财政年份:2010
-
负责人:Alan P. Fields
-
依托单位:
Atypical PKC signaling in lung cancer stem cells
-
批准号:8100459
-
项目类别:
-
资助金额:$19.62万
-
财政年份:2010
-
负责人:Alan P. Fields
-
依托单位:
Atypical PKC signaling in lung cancer stem cells
-
批准号:7939191
-
项目类别:
-
资助金额:$16.86万
-
财政年份:2010
-
负责人:Alan P. Fields
-
依托单位:
Atypical PKC signaling in lung cancer stem cells
-
批准号:8142296
-
项目类别:
-
资助金额:$8.03万
-
财政年份:2010
-
负责人:Alan P. Fields
-
依托单位:
Lipid Signaling Pathways in Cancer
-
批准号:7748739
-
项目类别:
-
资助金额:$0.6万
-
财政年份:2009
-
负责人:Alan P. Fields
-
依托单位:
Lipid Signaling Pathways in Cancer
-
批准号:7922156
-
项目类别:
-
资助金额:$0.2万
-
财政年份:2009
-
负责人:Alan P. Fields
-
依托单位:
LIPID SIGNALLING IN THE CELL NUCLEUS
-
批准号:6800958
-
项目类别:
-
资助金额:$2.83万
-
财政年份:2000
-
负责人:Alan P. Fields
-
依托单位:
LIPID SIGNALLING IN THE CELL NUCLEUS
-
批准号:6530100
-
项目类别:
-
资助金额:$0.96万
-
财政年份:2000
-
负责人:Alan P. Fields
-
依托单位:
LIPID SIGNALLING IN THE CELL NUCLEUS
-
批准号:6395006
-
项目类别:
-
资助金额:$3.81万
-
财政年份:2000
-
负责人:Alan P. Fields
-
依托单位:
LIPID SIGNALLING IN THE CELL NUCLEUS
-
批准号:6199584
-
项目类别:
-
资助金额:$3.78万
-
财政年份:2000
-
负责人:Alan P. Fields
-
依托单位:
Protein Kinase C Signaling Mechanisms in Cancer
-
批准号:10417167
-
项目类别:
-
资助金额:$46.94万
-
财政年份:1999
-
负责人:Alan P. Fields
-
依托单位:
Role of Protein Kinase C in Colon Carcinogenesis
-
批准号:7122483
-
项目类别:
-
资助金额:$42.53万
-
财政年份:1999
-
负责人:Alan P. Fields
-
依托单位:
海外基金